---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018020"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:36:52.631000+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics closes $11.6M Series B-1 preferred offering; appoints Dennis Matheis to board

## Summary
- Gross proceeds from combined Series B / B-1 offering total $29.8M; $11.6M from Series B-1, $18.6M from prior Series B.
- Series B-1 convertible at $0.7228/share after 6-month anniversary; dividends in stock on first and second anniversary.
- Dennis Matheis, President/CEO of Sentara Health ($13B revenue), appointed Class A director effective May 6, 2024.
- Proceeds to extend working capital runway as company approaches critical reimbursement milestones.

## SEC filing metadata
- accession: 0001493152-24-018020
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.02, 3.03, 5.03, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315224018020/0001493152-24-018020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315224018020/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018020
- JSON: https://secwatch.observer/filing/0001493152-24-018020.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018020.txt

## Key facts
- Executive change
  Dennis Matheis was appointed as Class A Director at Lucid Diagnostics Inc..
  - Action: appointed
  - Role: Class A Director
  source text: Effective May 6, 2024, the board of directors of the Company appointed Dennis Matheis as a Class A director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799011/000149315224018020/0001493152-24-018020-index.htm
- Governance Changes
  Lucid Diagnostics Inc.: Amended and Restated Certificate of Incorporation authorizes up to 20 million shares of preferred stock and designates Series B-1 Preferred Stock.
  - Change: charter amendment
  source text: Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. The information set forth under Item 3.02 is incorporated herein by reference. The Amended and Restated Certificate of Incorporation of the Company authorizes the issuance of up to 20,000,000 shares of preferred stock, par value $0.001 per share, and further authorizes the Board of the Company to fix and determine the designation, preferences, conversion rights, or other rights, including voting rights, qualifications, limitations, or restrictions of the preferred stock. The Certificate of Designation designates up to 11,634 of the shares of preferred stock as Series B-1 Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799011/000149315224018020/0001493152-24-018020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.